These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

287 related items for PubMed ID: 25743816

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for stage IV esophageal squamous cell carcinoma: a retrospective controlled study.
    Lyu J, Li T, Wang Q, Li F, Diao P, Liu L, Li C, Lang J.
    Radiat Oncol; 2018 Nov 26; 13(1):233. PubMed ID: 30477531
    [Abstract] [Full Text] [Related]

  • 3. Long-term results of concurrent chemoradiotherapy with daily-low-dose continuous infusion of 5-fluorouracil and cisplatin (LDFP) for Stage I-II esophageal carcinoma.
    Kumabe A, Fukada J, Kota R, Koike N, Shiraishi Y, Seki S, Yoshida K, Kitagawa Y, Shigematsu N.
    Dis Esophagus; 2018 Apr 01; 31(4):. PubMed ID: 29228166
    [Abstract] [Full Text] [Related]

  • 4. Salvage treatment for lymph node recurrence after radical resection of esophageal squamous cell carcinoma.
    Chen J, Yin W, Yao H, Gu W.
    Radiat Oncol; 2019 Sep 18; 14(1):169. PubMed ID: 31533757
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Feasibility and efficiency of concurrent chemoradiotherapy with a single agent or double agents vs radiotherapy alone for elderly patients with esophageal squamous cell carcinoma: Experience of two centers.
    Huang C, Zhu Y, Li Q, Zhang W, Liu H, Zhang W, Hu Y, Yuan Y, Liu M.
    Cancer Med; 2019 Jan 18; 8(1):28-39. PubMed ID: 30600600
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Definite intensity-modulated radiotherapy with concurrent chemotherapy more than 4 cycles improved survival for patients with locally-advanced or inoperable esophageal squamous cell carcinoma.
    Hsieh HY, Hsu CP, Yeh HL, Chuang CY, Lin JF, Chang CF.
    Kaohsiung J Med Sci; 2018 May 18; 34(5):281-289. PubMed ID: 29699635
    [Abstract] [Full Text] [Related]

  • 10. High serum levels of vascular endothelial growth factor-A and transforming growth factor-β1 before neoadjuvant chemoradiotherapy predict poor outcomes in patients with esophageal squamous cell carcinoma receiving combined modality therapy.
    Cheng JC, Graber MS, Hsu FM, Tsai CL, Castaneda L, Lee JM, Chang DT, Koong AC.
    Ann Surg Oncol; 2014 Jul 18; 21(7):2361-8. PubMed ID: 24623035
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
    Park JW, Kim JH, Choi EK, Lee SW, Yoon SM, Song SY, Lee YS, Kim SB, Park SI, Ahn SD.
    Int J Radiat Oncol Biol Phys; 2011 Nov 01; 81(3):691-7. PubMed ID: 20888705
    [Abstract] [Full Text] [Related]

  • 15. REG1A expression status suggests chemosensitivity among advanced thoracic esophageal squamous cell carcinoma patients treated with esophagectomy followed by adjuvant chemotherapy.
    Sato Y, Motoyama S, Nanjo H, Ito S, Yoshino K, Sasaki T, Kuribayashi K, Nagaki Y, Imai K, Saito H, Minamiya Y, Ogawa J.
    Ann Surg Oncol; 2013 Sep 01; 20(9):3044-51. PubMed ID: 23645481
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Tolerance and efficacy of dose escalation using IMRT combined with chemotherapy for unresectable esophageal carcinoma: Long-term results of 51 patients.
    Modesto A, Dalmasso C, Lusque A, Vieillevigne L, Izar F, Moyal E, Carrère N, Guimbaud R, Rives M.
    Cancer Radiother; 2020 Apr 01; 24(2):88-92. PubMed ID: 32156457
    [Abstract] [Full Text] [Related]

  • 20. Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma.
    Kato K, Nakajima TE, Ito Y, Katada C, Ishiyama H, Tokunaga SY, Tanaka M, Hironaka S, Hashimoto T, Ura T, Kodaira T, Yoshimura K.
    Jpn J Clin Oncol; 2013 Jun 01; 43(6):608-15. PubMed ID: 23585687
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.